Ryan, Colm J. http://orcid.org/0000-0003-2750-9854
Devakumar, Lovely Paul Solomon http://orcid.org/0009-0003-9838-0012
Pettitt, Stephen J. http://orcid.org/0000-0003-3313-3857
Lord, Christopher J. http://orcid.org/0000-0002-3226-0515
Funding for this research was provided by:
Breast Cancer Now
Cancer Research UK
Basser Foundation
Science Foundation
Article History
Received: 20 April 2023
Accepted: 4 October 2023
First Online: 30 November 2023
Competing interests
: C.J.L. makes the following disclosures: he receives and/or has received research funding from AstraZeneca, Merck and Artios; he received consultancy, SAB membership or honoraria payments from Syncona, Sun Pharma, Gerson Lehrman Group, Merck, Vertex, AstraZeneca, Tango, Third Rock, Ono Pharma, Artios, Abingworth, Tesselate, Dark Blue Therapeutics, Pontifax, Astex, NeoPhore and GlaxoSmithKline; he has stock in Tango, Ovibio, Hysplex and Tesselate. C.J.L. is also a named inventor on patents describing the use of DNA-repair inhibitors and stands to gain from their development and use as part of the ICR ‘Rewards to Inventors’ scheme and also reports benefits from this scheme associated with patents for PARPi paid into C.J.L.’s personal account and research accounts at the Institute of Cancer Research. C.J.R., L.P.S.D. and S.J.P. have no competing interests to declare.